EGFR and non-small cell lung carcinoma: In this report, we hypothesized that the combination of TUSC2 gene restoration and erlotinib treatment could enhance antitumor therapeutic efficacy in wild type EGFR NSCLC cells, characterized as erlotinib-resistant.